Free Trial
NASDAQ:TNGX

Tango Therapeutics (TNGX) Stock Price, News & Analysis

Tango Therapeutics logo
$6.11 +0.07 (+1.16%)
Closing price 04:00 PM Eastern
Extended Trading
$6.04 -0.07 (-1.13%)
As of 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Tango Therapeutics Stock (NASDAQ:TNGX)

Key Stats

Today's Range
$5.86
$6.20
50-Day Range
$1.10
$6.04
52-Week Range
$1.03
$12.02
Volume
1.59 million shs
Average Volume
1.60 million shs
Market Capitalization
$662.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.20
Consensus Rating
Buy

Company Overview

Tango Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
45th Percentile Overall Score

TNGX MarketRank™: 

Tango Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 647th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Tango Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Tango Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Tango Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Tango Therapeutics are expected to decrease in the coming year, from ($1.19) to ($1.38) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Tango Therapeutics is -4.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Tango Therapeutics is -4.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Tango Therapeutics has a P/B Ratio of 3.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Tango Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    26.60% of the float of Tango Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Tango Therapeutics has a short interest ratio ("days to cover") of 6.5.
  • Change versus previous month

    Short interest in Tango Therapeutics has recently decreased by 1.76%, indicating that investor sentiment is improving.
  • Dividend Yield

    Tango Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Tango Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    26.60% of the float of Tango Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Tango Therapeutics has a short interest ratio ("days to cover") of 6.5.
  • Change versus previous month

    Short interest in Tango Therapeutics has recently decreased by 1.76%, indicating that investor sentiment is improving.
  • News Sentiment

    Tango Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Tango Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    6 people have searched for TNGX on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Tango Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Tango Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.50% of the stock of Tango Therapeutics is held by insiders.

  • Percentage Held by Institutions

    78.99% of the stock of Tango Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Tango Therapeutics' insider trading history.
Receive TNGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tango Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TNGX Stock News Headlines

I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
See More Headlines

TNGX Stock Analysis - Frequently Asked Questions

Tango Therapeutics' stock was trading at $3.09 on January 1st, 2025. Since then, TNGX shares have increased by 96.1% and is now trading at $6.0610.

Tango Therapeutics, Inc. (NASDAQ:TNGX) issued its earnings results on Monday, May, 12th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.02. The firm earned $5.39 million during the quarter, compared to analyst estimates of $6.73 million. Tango Therapeutics had a negative net margin of 322.67% and a negative trailing twelve-month return on equity of 62.75%.

Shares of TNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tango Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Palo Alto Networks (PANW), Adobe (ADBE) and ServiceNow (NOW).

Company Calendar

Last Earnings
5/12/2025
Today
7/10/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TNGX
CIK
1819133
Fax
N/A
Employees
90
Year Founded
N/A

Price Target and Rating

High Price Target
$19.00
Low Price Target
$8.00
Potential Upside/Downside
+102.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$130.30 million
Net Margins
-322.67%
Pretax Margin
-322.17%

Debt

Sales & Book Value

Annual Sales
$42.07 million
Price / Cash Flow
N/A
Book Value
$1.86 per share
Price / Book
3.25

Miscellaneous

Free Float
100,264,000
Market Cap
$654.68 million
Optionable
Optionable
Beta
1.63
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:TNGX) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners